People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Edison Pharmaceuticals Inc | — | Biotechnology | Series C | $80.2M | $2.0B | 2009 |
| WOBF Holdings 1, LLC | — | Other | Series A | $4.4M | $11.0M | — |
Paul Avery at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Avery on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Cheng | 1 | 9 |
| Taro Inaba | 1 | 4 |
| Carl E. Berg | 1 | 3 |
| Carl Berg | 1 | 3 |
| Guy Miller | 1 | 2 |
| Forrest Sawyer | 1 | 2 |
| James Pollard | 1 | 1 |
| Chris Kelsch | 1 | 1 |
| Matthew LaFon | 1 | 1 |
| Scott Zepp | 1 | 1 |
| Benjamin Novello | 1 | 1 |
| Martin E. Thoolen | 1 | 1 |
| Forrest E. Sawyer | 1 | 1 |
| Martine Thoolen | 1 | 1 |
| Keith Tsukimura | 1 | 1 |
| Martin Thoolen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.